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Mesenchymal stem cells (MSCs) play an important role in the pathology of preeclampsia (PE). Our
previous microarray analysis found that microRNA-494 (miR-494) is highly expressed in decidua-
derived MSCs (dMSCs) from PE. We hypothesized that aberrant expression of miR-494 in dMSCs is
involved in PE development. In the present study, we found that miR-494 arrests G1/S transition
in dMSCs by targeting CDK6 and CCND1. We also found that supernatant frommiR-494-overexpress-
ing dMSCs reduces HTR-8/SVneo migration and impairs HUVEC capillary formation by suppressing
VEGF. Taken together, we report an unrecognized mechanism of miR-494 affecting dMSC prolif-
eration and function in the pathology of PE.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction maternal–fetal interface, which determines the success of preg-Preeclampsia (PE) is a pregnancy-speciﬁc multi-organ dysfunc-
tional disease and a leading cause of maternal and fetal morbidity
and mortality worldwide [1,2]. Its multifactorial pathogenesis is
still not clearly elucidated [3–5]. It was reported that insufﬁciency
of angiogenesis might be one of the most important factors [6]. A
ﬁne balance between pro-angiogenic and anti-angiogenic factors
was pivotal in vascular development of angiogenic processes atnancy [7]. However, the expression of angiogenic growth factors
was signiﬁcantly altered in placenta and serum of pregnancies
complicated with PE [8–11].
Mesenchymal stem cells (MSCs), capable of self-renewal,
expansion and multilineage differentiation [12,13], are thought
to be multifunctional stem cells and can be derived from various
tissues [14]. Many studies reported that MSCs play various roles
both in immune-regulatory potential and in vasculogenesis and
angiogenesis [15,16]. MSCs regulate the immune system by affect-
ing the proliferation, maturation and function of immune cells
[17,18]. MSCs also secret a broad range of bioactive molecules,
such as vascular endothelial growth factor (VEGF), interleukin-6
(IL-6) and monocyte chemoattractant protein-1 (MCP-1), to dis-
play angiogenesis [16,19,20]. Interestingly, recent studies reported
that MSCs in maternal–fetal interface could maintain successful
pregnancy. The changes in MSCs’ function might cause gestational
related diseases and be involved in the imbalanced angiogenesis in
maternal–fetal interface of PE [15]. However, it is still remains
unclear on the molecular mechanism of angiogenic regulation of
MSCs in maternal–fetal interface.
MicroRNAs (miRNAs or miRs) are a class of evolutionarily con-
served and widespread small non-coding RNAs through inhibiting
translation or direct cleavage of target mRNAs to regulate various
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eration, cell cycle, differentiation and apoptosis [21]. It was found
that the expression proﬁles of miRNAs were signiﬁcantly altered in
MSCs, placenta tissues, maternal serum, and umbilical cord blood
from PE pregnancies [22–25]. Our previous studies showed that
miR-16 inhibited the angiogenesis potential of MSCs and miR-
181a modulated local immune balance in PE [26,27]. And our
miRNA array analysis results showed that microRNA-494-3p
(miR-494) is one of the most high expressed miRNAs in decidua-
derived MSCs (dMSCs) from patients with PE [26,28]. miR-494
was reported to suppress arterial endothelial cell proliferation
[29] and be involved in neovascularization [30]. These data suggest
that miR-494 may act as an important regulator to be involved in
angiogenesis in maternal–fetal interface of PE.
Thus, in the present study, we are engaged to explore the func-
tion of miR-494 on dMSCs. We found that miR-494 affected cell
growth and the paracrine activity of dMSCs and inhibited tro-
phoblastic cell migration and tube formation of endothelial cells,
suggesting that miR-494 may be involved in the pathology of PE.
2. Materials and methods
2.1. Decidua collection
Decidua tissues were obtained from placental site decidua
basalis of healthy pregnancies (n = 10) and PE pregnancies (n = 5)
who underwent Caesarean section in Drum Tower hospital from
Jan 2014 through Sep 2014. Nanjing Drum Tower hospital
ethics-committee approved and the patients had written consent.
Criteria for exclusion were multiple gestations and the presence
of maternal chronic hypertension, chronic nephritis, hepatic
disease, the HELLP syndrome, gestational diabetes mellitus, in vitro
fertilization and embryo transfer (IVF-ET) and mild preeclampsia
or other infectious and neoplastic disease and fetal congenital
defect.
2.2. dMSCs isolation and culture
dMSCs were isolated from fresh decidua tissues. The process
was operated within 4 h as we previously reported in our laborato-
ry [31]. Decidua tissues were washed with PBS several times and
mechanically broken to pieces and incubated in an enzyme cocktail
(Sigma, St. Louis, MO) 1 h with gentle agitation at 37 C. The diges-
tion mixture was washed with PBS and then washed with Dulbec-
co’s modiﬁed Eagle’s medium/F12 (DF12, Gibco, Grand Island, NY,
USA). Then they were suspended in fresh DF12 supplemented with
20% fetal bovine serum (FBS) plus antibiotics and incubated at
37 C in a 5% CO2 saturating humidiﬁed atmosphere. Two days
after the incubation, the small digested residues were removed
and the culture was continued. The medium was replaced two
times every week. When numerous colonies were observed, cells
were detached using 0.25% trypsin/EDTA to transfer to a new cul-
ture plate supplemented with 10% fetal bovine serum. After the
2nd to 4th cell passages, the speciﬁc phenotypic surface antigens
of MSCs were characterized by ﬂow cytometry assay. The adherent,
ﬁbroblast-like cells were presented as CD105+, CD73+, CD90+,
CD29+, CD44+, CD106-, HLA-DR-, CD11b-, CD14-, CD34-, CD31-
and CD45- (Fig. S1). dMSCs also could differentiate into adipose,
chondrocyte and bone as we previously reported [31].
2.3. Cell line and culture
HTR-8/SVneo cells and human umbilical vein endothelial cells
(HUVEC) were cultured in RPMI-1640 (Gibco) supplemented with
10% FBS and 100 IU/mL antibiotics, at 37 C in a humidiﬁed
atmosphere with 5% CO2.2.4. Transient transfection
Overexpression of miR-494 in dMSCs was achieved by trans-
fecting cells with miR-494 mimic (mi-494) and miR-494 mimic
negative control (mi-NC) (RIBO BIO, Guangzhou, China) using lipo-
fectimine 2000 reagent (Invitrogen) until dMSCs reached 30–50%
conﬂuence and represented a good growth state. Three sequences
of small interfering RNAs for VEGF (si-VEGF) were ordered from
RIBO BIO. After transfection for 48 h, cells and the supernatants
were harvested for the following experiments.
2.5. Cell viability analysis
Cell viability was performed by using a CCK-8 kit (DojinDo) to
detect the effect of miR-494 on dMSCs’ viability. A cell counting
kit was used to receive a qualitative index of cell viability after
transfection in our experiments. After transfection for 48 h, CCK-
8 was separately added to each well and incubation for another
3 h. An OD absorbance at 450 nm was measured by a multi-detec-
tion micro plate reader (HynergyTM HT; Bio-Tek, Winooski, USA).
All experiments were performed in triplicate (n = 3).
2.6. Cell cycle and apoptosis analysis
Cell cycle and apoptosis analysis were carried out in order to
detect the effect of miR-494 on dMSCs’. Brieﬂy for cell cycle, 48 h
after transfection, cells were ﬁxed in cold 70% ethanol for incuba-
tion overnight at 4 C. After washedwith PBS twice, cells were incu-
bated with 50 lg/mL propidium iodide (PI) and 20lg/mL RNase A
for 30 min at room temperature and were detected by FACs. Analy-
sis was performed with ModFit 3.0 software. For apoptosis assay,
48 h after transfection, cells and their supernatants were harvested
and washed with PBS. Annexin V was added to the suspended cells
and incubated at 4 C for 15 min in the dark. Then PI was added for
incubation for 5 min in the dark. Cells without addition of Annexin
V were used as a negative control. And cells were detected by FACs.
Analysis was performed with Cell Quest software (BD Biosciences).
All experiments were repeated (n = 5).
2.7. Proliferation analysis
Proliferation analysis was performed to test whether miR-494
had an effect on dMSCs. dMSCs were pre-treated with or without
5,6-carboxyﬂuorescein diacetate, succinimidyl ester (CFSE). After
72 h transfection, dMSCs were harvested and washed with PBS to
be detected by FACs. Proliferation index analysis was performed
with ModFit 3.0 software. The proliferation index, a statistic gener-
ated by ModFit that relates to the number of population doublings
the dMSCs had undergone following CFSE loading, was used
[32,33]. All experiments were performed in triplicate (n = 3).
2.8. Total RNA isolation and q-PCR analysis
Brieﬂy, total RNA, including miRNAs, was extracted using Trizol
reagent (Invitrogen). The concentration of RNA was measured
using a SmartSpecTM Plus spectrophotometer (Bio-Rad, Hercules,
CA, USA). Then 1 lg total RNA was reverse-transcribed into cDNA
using reverse transcriptase, reverse transcriptase buffer, dNTPs,
RNase inhibitor and OligodT in the Thermoscript (TaKaRa). The
cDNA obtained was used for real-time quantitative PCR (q-PCR)
by using an Applied Bio-Systems step-one detection system with
SYBR green dye (Invitrogen). For relative quantiﬁcation of the
mRNA expression, the expression of tubulin was used as an
endogenous control [34]. The method to quantify mature miRNAs
was performed by stem-loop RT-PCR. 1 lg miRNA and primers
were put at 65 C for 5 min to form highly target-speciﬁc
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dNTPs and 5 buffer were added for reverse transcription. The
whole procedure was performed on ice. Besides, the miRNAs
ampliﬁcation was performed by using an Applied Bio-Systems
step-one detection system with SYBR green dye (Invitrogen). The
primers of the genes for q-PCR were listed in Table S1. All experi-
ments were performed in triplicate (n = 3). Relative expression was
performed using the DDCt method.
2.9. Western blot analysis
Whole-cell lystes for western blotting were extracted with lysis
buffer and protease inhibitor (Roche). Lysates (30 lg) dMSCs were
electrophoresed by SDS/PAGE (10% gel) (Bio-Rad Laboratories) and
electroblotted on to PVDF membranes (Roche). After blocking, the
membranes were incubated overnight at 4 C with primary anti-
bodies against VEGF (Bioworld), cyclin D1 (CCND1), cell cycle
dependent kinase 6 (CDK6), Tubulin (Cell Signaling Technology,
Danvers, MA, USA) [35]. Then the membranes were followed by
incubation with secondary antibodies linked to HRP (horseradish
peroxidase (Cell Signalling Technology)). The blots were visualized
using an enhanced Immobilon Western chemiluminescent horse-
radish peroxidase substrate (Millipore, Billerica, MA), according
to the manufacturers’ instructions, and the relative intensity of
the speciﬁc bands was quantiﬁed using the FluorChem FC2 system
(Alpha Innotech Corporation, San Leandro, CA, USA). All experi-
ments were repeated at least three times.
2.10. ELISA analysis
The expression of secreted VEGF in the supernatants of dMSCs
transfected with miRNAs oligonucleotides or si-VEGF was detectedFig. 1. Overexpressed miR-494 reduces cell viability and the capability of proliferation in
494 mimic negative control (mi-NC). After 48 h transfection, the OD absorbance at 450 n
CFSE transfected with mi-494 or mi-NC was determined using ﬂow cytometry assay,
transfected with mi-494 or mi-NC. After 48 h transfection, annexin V assay was performe
was shown in images (left) and histogram (right). Values are means ± S.E.M. The resu
difference compared with negative control group (P < 0.01).using a speciﬁc commercial ELISA kit (DAKEWE) for VEGF. After
48 h transfection, the cell supernatants were collected and cen-
trifuged at 12000g for 10 min, subsequently preserved at
80 C. All experiments were performed in triplicate (n = 3).
2.11. Dual-luciferase assay
The ﬁreﬂy luciferase plasmid of VEGF part segments of 30 UTR
(un-translated region), position from 1351 to 1751, which con-
tains the two putative binding sites, was constructed in a pGL3
control at an XbaI-cloning site by GENEray (GENEray Biotech-
nology, Shanghai). Co-transfection of mi-494 or mi-NC and plas-
mids of ﬁreﬂy luciferase containing VEGF binding site (200 ng)
and Renilla luciferase reporter (20 ng) was transiently transfected
into the cells. After 24 h, the ﬁreﬂy and Renilla luciferase activ-
ities were measured consecutively using Dual Luciferase Assay
(Promega).
2.12. HTR-8/SVneo migration assay
The transwell migration assay was performed by using tran-
swell membrane ﬁlters (8-lm size pore, Millipore). Supernatants
were added to the lower chamber, and 100 lL HTR-8/SVneo cells
were seeded in the upper chamber at a density of 2  105/mL. After
24 h incubation, non-migrating cells on the upper surface of the
membrane were removed with a cotton swab. The migrated cells
on the lower surface of the membranes were ﬁxed with 10% for-
malin for 30 min at room temperature, stained with crystal violet
solution for 20 min. After washed with distilled water, ten random-
ly chosen ﬁelds were imaged and quantiﬁed by blind counting of
the migrated cells of ten ﬁelds per chamber. All experiments were
performed in triplicate (n = 3).dMSCs. (A) CCK-8 assay of dMSCs transfected with miR-494 mimic (mi-494) or miR-
m was detected on a plate reader. (B) Cell proliferation of dMSCs pre-staining with
showing in images (left) and histogram (right). (C) Annexin V/PI assay of dMSCs
d using ﬂow cytometry assay. Percentage of apoptosis cells (early and late apoptosis)
lts are representative of three independent experiments. ** Indicates signiﬁcant
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The HUVEC capillary-like tube formation assay was performed
on Matrigel (Solarbio). After the Matrigel coagulated, the plate
was added with 5  104 cells/well and equal volume of super-
natants. Cells on Matrigel were incubated for 8 h and ﬁve randomly
chosen ﬁelds were taken off and calculated by image pro plus soft-
ware. All experiments were performed in triplicate (n = 3).
2.14. Statistical analysis
All experiments were performed at least three times and data
are expressed as mean ± S.E.M. Graphpad prism version 5.01 was
used to perform graphics and the two-tailed Student t-test was
used to compare statistical signiﬁcance. P < 0.05 was set as a statis-
tical signiﬁcance.
3. Results
3.1. Overexpression of miR-494 inhibits the growth of dMSCs
To explore the effect of miR-494 on dMSCs cell growth, miR-494
mimics (mi-494) and miR-494 mimic negative control (mi-NC)
were transfected into dMSCs. As demonstrated by CCK-8 assay,
overexpressed miR-494 inhibited cell viability at 48 h (Fig. 1A).Fig. 2. Overexpressed miR-494 arrests cell cycle of dMSCs at G1/S transition. (A) dM
subsequently assayed for DNA content by ﬂow cytometry assay. Images are shown on the
for percentage of the cells in different phases of cell cycle. (B) and (C) The reduction expr
mRNA expression level of cdk6, ccnd1, ccne1 and ccnd2. (C) Western blot analysis of the l
the seed matches on human 30 UTR of CDK6, CCND1, CCND2 and CCNE1, respectively. D
* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001.Moreover, the inhibitory effect of miR-494 on dMSCs cell growth
was further conﬁrmed by the reduced proliferation index
(Fig. 1B). However, there was no signiﬁcant change in early and
late apoptosis of dMSCs when overexpressing of miR-494
(P = 0.7539 and P = 0.0589, respectively) (Fig. 1C). And the percent-
age of early and late apoptosis was 3.477 ± 0.1784 and
9.817 ± 0.6173, respectively, compared with dMSCs transfected
with mi-NC (3.567 ± 0.2000 and 14.80 ± 1.801, respectively).
3.2. Overexpression of miR-494 arrests cell cycle at G1/S transition in
dMSCs
Overexpression of miR-494 in dMSCs causing an inhibition in
cell growth, which was generally related with apoptosis and cell
cycle, we wondered whether overexpressed miR-494 could affect
cell cycles. The results showed that the percentage of dMSCs trans-
fected with mi-494 or mi-NC at G1 phase was 72.02 ± 0.2734 and
75.24 ± 0.8934, respectively; and the percentage of cells at S phase
was 21.32 ± 0.6553 and 16.75 ± 0.4447, respectively. It was
showed an increase at G1 phase and a decrease at S phase
(P = 0.0260 and 0.0045, respectively) (Fig. 2A). Furthermore, we
examined cell cycle related genes, and found that both cdk6 and
ccnd1 at mRNA and protein level had a signiﬁcant decrease in
dMSCs overexpressing of miR-494 (Fig. 2B and C). The mRNA
expression of ccne1 and ccnd2 had a lower level in dMSCs trans-SCs were transfected with mi-494 or mi-NC. After transfection 48 h, cells were
left panels for cell cycle distribution, and a statistical analysis is shown on the right
ession of cell cycle related genes in dMSCs transfected with mi-494. (B) The relative
evels of CDK6 and CCND1. (D) Predicted binding sites between the miR-494 seed and
ata are representative of three independent experiments. Values are means ± S.E.M.
Fig. 3. Overexpressed miR-494 reduces the expression of secreted VEGF of dMSCs.
(A) Predicted interaction between the miR-494 seed and the seed matches on
human 30 UTR of VEGF. (B) Analysis of luciferase intensity in cells co-transfected
with mi-494 or mi-NC, pGL3 containing the 30 UTR of VEGF, and the Renilla
luciferase reporter plasmid. After 24 h of transfection, cells were assayed using
luciferase assay kit (Promega). (C) Quantitative reverse transcription polymerase
chain reaction (q-PCR) analysis of the mRNA expression of vegf. The relative
expression of vegf was performed after 48 h transfection. (D) Analysis of the
concentration of secreted VEGF in supernatant by ELISA. The concentration was
assayed after transfection with mi-494 or mi-NC. All data are representative of
three independent experiments. * Indicates P < 0.05, ** indicates P < 0.01.
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tion software (www.targetscan.org, www.microrna.org) showed
that CDK6, CCND1, cyclin D2 (CCND2), and cyclin E1 (CCNE1) are
all putative target of miR-494 (Fig. 2D).
3.3. Overexpression of miR-494 suppresses expression of VEGF in
dMSCs
VEGF is an important soluble active mediator secreted by MSCs.
Through bio-information analysis (www.microrna.org), we found
that VEGF was a putative target gene of miR-494. There are miR-
494 binding sequences in 30 UTR of VEGF gene (Fig. 3A). Then
dual-luciferase assay was performed to test the direct interaction
between VEGF and miR-494. As shown in Fig. 3B, the relative luci-
ferase intensity was signiﬁcantly decreased in cells cotransfected
with mi-494 and reporter plasmids containing the 30 UTR of VEGF
for 24 h compared with that in mi-NC transfected cells. Further-
more, the effects of miR-494 on VEGF mRNA and protein in dMSCs
were analyzed. We found that VEGF expression was signiﬁcantly
reduced in dMSCs both at mRNA level (Fig. 3C) and protein level
(Fig. 3D).
3.4. Supernatant from miR-494-overexpressed dMSCs inhibits HTR-8/
SVneo migration and impairs HUVEC capillary formation in vitro
As VEGF, the only speciﬁc mitogen for endothelial cells, pro-
motes vasculogenesis and angiogenesis [36], we explored whether
supernatant of dMSCs overexpressing of miR-494 had a virtually
effect on angiogenesis through targeting VEGF. Firstly, we
introduced small interfering RNA for VEGF (si-VEGF) as a positivecontrol. We selected one sequence of si-VEGF as our ideal candi-
date due to its perfect interfering efﬁciency in the reduction of
VEGF expression level (Fig. 4A and B). Then we performed migra-
tion assay and tube formation assay by using conditioned medium
collected from dMSCs transfected with mi-494, mi-NC, si-VEGF
and its negative control, respectively. The number of migrated cells
on the bottom of transwell in mi-NC group was similar with NC
group (55.33 ± 3.590 vs 49.00 ± 8.781, P > 0.05) (Fig. 4C). However,
the number of migrated cells in mi-494 group was decreased sig-
niﬁcantly (22.67 ± 2.916, P < 0.01) (Fig. 4C). si-VEGF group was as
positive control (11.67 ± 0.8819, P < 0.05). Tube formation analysis
results showed that the relative tubes length of tube-like capillary
(% control) on Matrigel was 1.000 ± 0.07612 in mi-NC group and
1.000 ± 0.1167 in NC group (P > 0.05) (Fig. 4D). The relative tubes
length was signiﬁcantly reduced in mi-494 group (0.7256 ±
0.01881, P < 0.05) and in si-VEGF positive control group
(0.4433 ± 0.03946, P < 0.01) (Fig. 4D).
3.5. Conditioned medium of dMSCs obtained from PE pregnancies
inhibits migration of HTR-8/SVneo and impairs angiogenesis of HUVEC
We then detected the expression of miR-494 and VEGF in dMSCs
obtained from healthy pregnancies and PE pregnancies. We found
the elevated expression of miR-494 and the reduced expression of
VEGF in dMSCs from PE pregnancies (Fig. 5A and B). Moreover,
phosphorylation of AKT (p-Akt), the downstream signaling path-
way of VEGF, was checked in dMSCs obtained from PE pregnancies.
As shown in Fig. 5B, the activity of p-Akt was inhibited in PE
patients derived dMSCs. To further identify the inhibitory effect of
miR-494 on VEGF expression, we transfected miR-494 inhibitor
into PE patients derived dMSCs and we found VEGF protein and
secreted VEGF were both increased (Fig. 5C). Subsequently, we col-
lected conditioned medium (CM) of dMSCs obtained from PE preg-
nancies and healthy pregnancies, respectively, then the CM was
used to treat HTR-8/SVneo for migration analysis and HUVEC for
tube formation analysis. As shown in Fig. 5D and E, CM of dMSCs
from PE pregnancies inhibited the migration and tube formation
compared with that from healthy pregnancies.4. Discussion
The maternal–fetal interface is an important source of MSCs
[37,38]. Aberrant levels of cytokines were observed in placenta-
derived MSCs from patients with PE [39]. These ﬁndings suggest
that abnormal MSCs may contribute to PE development. In our pre-
vious study, we found that miR-494 was signiﬁcantly up-regulated
in dMSC from PE patients [28]. Therefore, we speculated that miR-
494 in dMSCs may be involved in the pathogenesis of PE. In the
present study, we found that overexpressed miR-494 inhibited cell
growth and arrested cell cycle at G1/S transition by targeting
cyclin, but did not affect cell apoptosis. Moreover, miR-494
decreased the secretion of VEGF, leading to a reduction of tro-
phoblastic cells migration and endothelial cell tube formation.
These ﬁndings suggest that miR-494 may be involved in the poor
angiogenesis of placenta in PE.
Recently, numerous studies show that miR-494 plays an impor-
tant role in the cell proliferation and function. It was reported that
miR-494 involves in senescence of human diploid ﬁbroblasts [40].
miR-494 can inhibit the proliferation, invasion, and migration in
prostate cancer cells by targeting CXCR4 [41]. miR-494 was also
reported to involve in chemoresistance in small cell lung cancer
[42]. In our study, we found that miR-494 inhibited the prolif-
eration of dMSCs by targeting cyclin. And we found that miR-494
inhibited angiogenesis by targeting VEGF. Welten et al. also report-
ed that inhibition miR-494 increases neovascularization and blood
Fig. 4. Supernatant frommiR-494-overexpressed-dMSCs inhibits HTR-8/SVneo migration and HUVEC tube formation. (A) Q-PCR analysis of the mRNA expression of vegf. The
relative expression level was assayed in dMSCs transfected with si-RNA negative control oligonucleotide (NC), si-VEGF-1, si-VEGF-2 and si-VEGF-3 for 48 h. (B) ELISA assay of
the secreted protein level of VEGF. The concentration was performed at 48 h after transfection with si-VEGF-1. (C) Analysis of migrated HTR-8/SVneo cells treated with
supernatant. HTR-8/SVneo cells were treated with supernatant from dMSCs transfected with mi-NC, mi-494, NC and si-VEGF. The number of migrated cells was quantiﬁed
using a microscope at 100 magniﬁcation. Representative images are shown on the left panels and a statistical analysis is shown on the right. (D) Analysis of HUVEC tube
formation. HUVEC was treated with supernatant from dMSCs transfected with mi-NC, mi-494, NC and si-VEGF. The tubes were photographed under a microscope at 500
magniﬁcation. Representative images are shown on the left panels and a statistical analysis is shown on the right. All results are from three independent experiments. Values
are means ± S.E.M. * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001.
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ed to target hypoxia-inducible factor-1 alpha, which is an impor-
tant molecular in PE pathology [43].
In our study, miR-494 has no signiﬁcant effect on dMSCs’ apop-
tosis, but shows a strong trend in decreasing late apoptosis. How-
ever, the effect of miR-494 on dMSCs’ apoptosis is inconsistent. In
an ischemia/reperfusion (I/R)-induced cardiac injury, transgenic
hearts with cardiac-speciﬁc overexpression of miR-494 show
remarkable decreases in apoptosis [44]. But miR-494 over-expres-
sion provokes apoptosis and inhibits gastrointestinal stromal
tumors (GIST) cell growth in GIST882 [45]. Moreover, it is reported
that miR-494 has no effect on cell apoptosis in A549 cells with con-
stitutive expression of miR-494. It only inhibits the proliferation
and colony forming activity in A549 but does not affect the activ-
ities of caspase-3 and -7 [29]. The discrepancy can be explainedby following: miR-494 has hundreds of potential target genes
involved in apoptosis, mainly in 2 subgroups: proapoptotic and
antiapoptotic proteins; and it is likely that one microRNA can exert
opposite response in different cells through targeting different
genes.
However, there are some defects and limitations in some
respects. First, as we investigated the effect of miR-494 on dMSCs
and did not explore the combined effect of miR-494 with other
changed microRNAs, which were veriﬁed in dMSCs obtained from
PE pregnancies by Q-PCR, there is need to study furthermore.
Secondly, although some interesting phenomenon is investigated
about miR-494, but it is unknown whether miR-494 is of impor-
tance to cause the symptom of PE or inhibition of miR-494
can reverse the development of PE symptom in vivo. There is
need to further exploration. Moreover, we just explored the target
Fig. 5. Conditioned medium of dMSCs obtained from PE pregnancies impairs migration and angiogenesis. (A) The expression level of miR-494 was assayed by Q-PCR in
dMSCs from healthy and PE pregnancies (n = 5). (B) Concentration of VEGF was assessed by ELISA and the expression of p-Akt and Akt proteins was analyzed by Western
blotting in dMSCs obtained from healthy and PE pregnancies (n = 3). (C) VEGF protein level in dMSCs from PE patients after transfection with miR-494 inhibitor (in-494) and
its negative control (in-NC) (n = 3). (D) Analysis of migrated HTR-8/SVneo cells treated with supernatant. HTR-8/SVneo cells were treated with supernatant of dMSCs obtained
from healthy and PE pregnancies. The migrated cells were photographed using a microscope at 100 magniﬁcation. (E) Analysis of HUVEC tube formation. HUVEC was
treated with supernatant of dMSCs obtained from healthy and PE pregnancies. The tubes were photographed under a microscope at 500 magniﬁcation. * Indicates P < 0.05,
** indicates P < 0.01.
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ing with VEGF-Akt-eNOS pathway need to be further researched.
Collectively, in our study, we work on the relationship between
MSCs and miR-494, attempting to explain how the highly
expressed microRNA plays the role in the development of PE. Over-
expressed miR-494 inhibits the growth and paracrine function of
MSCs by decreasing the expression of CDK6, CCND1 and VEGF,
respectively. The present study reveals that miR-494 arrests cell
cycle at G1/S transition and affects MSCs’ function of secreting
VEGF and may be a novel mechanism in the development of PE.
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